Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aethlon Medical (AEMD) Capital Expenditures (2016 - 2025)

Aethlon Medical filings provide 14 years of Capital Expenditures readings, the most recent being -$2192.0 for Q1 2025.

  • On a quarterly basis, Capital Expenditures fell 144.67% to -$2192.0 in Q1 2025 year-over-year; TTM through Dec 2024 was $7099.0, a 97.24% decrease, with the full-year FY2024 number at $250867.0, down 73.4% from a year prior.
  • Capital Expenditures hit -$2192.0 in Q1 2025 for Aethlon Medical, down from $2192.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $739165.0 in Q3 2022 to a low of -$2192.0 in Q1 2025.
  • Median Capital Expenditures over the past 5 years was $38374.0 (2021), compared with a mean of $103228.0.
  • Biggest five-year swings in Capital Expenditures: soared 3944.91% in 2022 and later crashed 144.67% in 2025.
  • Aethlon Medical's Capital Expenditures stood at $57934.0 in 2021, then surged by 161.48% to $151486.0 in 2022, then crashed by 94.19% to $8807.0 in 2023, then tumbled by 75.11% to $2192.0 in 2024, then tumbled by 200.0% to -$2192.0 in 2025.
  • The last three reported values for Capital Expenditures were -$2192.0 (Q1 2025), $2192.0 (Q4 2024), and $4907.0 (Q1 2024) per Business Quant data.